HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greer, J. B. Articles by Ness, R. B. Search for Related Content PubMed PubMed Citation Articles by Greer, J. B. Articles by Ness, R. B. Related Collections Epidemiology/public health Gynecologic oncology Reproductive endocrinology

Androgenic Progestins in Oral Contraceptives and the Risk of Epithelial Ovarian Cancer

From the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

OBJECTIVE: Oral contraceptives (OCs) have been consistently linked to reduced risk of ovarian cancer. Oral contraceptive formulations display varying degrees of androgenicity. Data linking androgens to ovarian cancer suggest that OC androgenicity may impact efficacy in preventing ovarian cancer. The authors investigated whether OC efficacy might differ according to androgenicity by using data from a large, population-based, case-control study (the Steroid Hormones and Reproductions [SHARE] Study).

METHODS: Detailed data on OC formulation was obtained by an in-person interview for 568 cases and 1,026 controls. Multivariable logistic regression was used to assess the association of OC androgenicity with ovarian cancer while controlling for the known potential confounders of age, parity, family history of ovarian cancer, and tubal ligation.

RESULTS: Androgenic and nonandrogenic OCs conferred a similar and significant reduction in ovarian cancer risk (odds ratio 0.52, 95% confidence interval 0.35–0.76 and odds ratio 0.59, 95% confidence interval 0.45–0.78, respectively). No differences in duration of use, age at first use, and time since last use were found between androgenic and nonandrogenic formulations.

CONCLUSION: In general, the androgenicity of an OC does not alter chemopreventive efficacy.

LEVEL OF EVIDENCE: II-2

This article has been cited by other articles:

				M. M. Hedderson, A. Ferrara, M. A. Williams, V. L. Holt, and N. S. Weiss Androgenicity of Progestins in Hormonal Contraceptives and the Risk of Gestational Diabetes Mellitus Diabetes Care, May 1, 2007; 30(5): 1062 - 1068. [Abstract] [Full Text] [PDF]

				Androgenic and Nonandrogenic OCs Protect Against Ovarian Cancer Journal Watch Women's Health, June 7, 2005; 2005(607): 5 - 5. [Full Text]